Brigatinib is an oral tyrosine kinase inhibitor approved in multiple countries for the treatment of patients with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer who have progressed on or are intolerant to crizotinib. We report a population pharmacokinetic model-based analysis for brigatinib.Plasma concentration–time data were collected from 442 participants (105 healthy volunteers and 337 patients with cancer) who received single or multiple doses of oral brigatinib in one of five trials. Data were analyzed using non-linear mixed-efects modeling (NONMEM software version 7.3).The result shows brigatinib plasma concentrations were best described by a three compartment model with a transit compartment input (number of transit compartments=2.35; mean transit time=0.9 h). The fnal model included albumin as a covariate on apparent clearance. None of the additional covariates examined, including sex, age, race, body weight, mild or moderate renal impairment, total b..... READ ARTICLE
SpringerLink DOI:10.1007/s40262-020-00929-4
Authors: Neeraj Gupta, Xiaohui Wang, Elliot Ofman, Marita Prohn, Narayana Narasimhan, David Kerstein. Michael J. Hanley, Karthik Venkatakrishnan
